Alnylam Pharma (ALNY) Tops Q3 EPS by $3.06
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $254.42 -2.18%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $1.74, $3.06 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $750.5 million versus the consensus estimate of $397.99 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18
- Signet Jewelers (SIG) Tops Q2 EPS by 47c, Misses on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
